EGFR and oropharynx cancer: Our findings of no objective responses in the HPV-positive group with either agent are consistent with those recently reported with afatanib (27), with no objective responses in the p16-positive population and a 13.5% response rate in the p16-negative population, and raise further doubts about the role of anti-EGFR monotherapy for R/M HPV-associated oropharyngeal cancer.